Table 2.
Primary and Secondary Outcome Measures at the 3- and 12-Month Follow-up
|
Usual Care (n = 59) |
Injection (n=60) |
|||||||
|---|---|---|---|---|---|---|---|---|
| Outcome | Baseline | 3 mo | 12 mo | Baseline | 3 mo | 12 mo | 3 mo OR (95% CI) | 12 mo OR (95%CI) |
| Recovered,n/N (%)a | – | 20/59 (34) | 33/55 (60) | – | 33/60 (55) | 34/56 (61) | 2.38 (1.14 to 5.00) | 1.05 (0.50 to 2.27) |
| Difference at 3 mo (95% CI)b | Difference at 12 mo (95% CI) | |||||||
| Pain at rest, mean (SD)c | 5.3 (2.2) | 3.7 (2.5) | 2.3 (2.3) | 5.1 (2.2) | 2.5 (2.5) | 2.1 (2.5) | 1.18 (0.31 to 2.05) | 0.14 (−0.75 to 1.04) |
| Pain with activity, mean (SD)c | 6.6 (2.60) | 4.8 (2.8) | 3.2 (2.9) | 6.7 (1.9) | 3.6 (2.8) | 2.8 (2.8) | 1.30 (0.32 to 2.29) | 0.45 (−0.55 to 1.46) |
| Secondary outcomes | ||||||||
| WOMAC pain, mean (SD)d | 52.4 (19.1) | 37.6 (22.7)1 | 22.9 (22.8) | 48.8 (16.1) | 23.6 (21.3) | 18 (19.6) | 12.40 (4.86 to 19.93) | 2.67 (−4.98 to 10.32) |
| WOMAC function, mean (SD)d | 49.2 (19.6) | 34.2 (21.3) | 21.7 (22.7) | 43.9 (17.0) | 21.3 (19.3) | 17.4 (19.6) | 11.36 (4.01 to 18.70) | 1.01 (−6.37 to 8.39) |
| EQ-5D, mean (SD)e | 0.72 (0.2) | 0.79 (0.17) | 0.85 (0.17) | 0.74 (0.2) | 0.81 (0.2) | 0.82 (0.2) | −0.02 (−0.08 to 0.04) | −0.004 (−0.05 to 0.06) |
EQ-5D = a quality-of-life instrument from EuroQol; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index.
a Fully or strongly recovered.
b Adjusted for baseline values of the outcome.
c Scored on a range from 0–10, where 0 = no pain and 10 = worst conceivable pain.
d Scored on a range from 0–100, with high values indicating more pain or lower physical functioning.
e Scored on a range from 0–1, where 0 = worst quality of life and 1 = best quality of life.